- $178.36m
- $157.43m
- $0.01m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.56 | ||
| Price to Tang. Book | 11.45 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 12,739.77 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -131.83% | ||
| Return on Equity | -119.83% | ||
| Operating Margin | -304535.71% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.01 | 0.18 | 0.37 | 0.15 | 0.01 | n/a | 5.41 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. The Company has three product platforms. The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune, developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that has completed a trial in recessive dystrophic epidermolysis bullosa.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 25th, 2015
- Public Since
- February 4th, 2019
- No. of Shareholders
- 28
- No. of Employees
- 22
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 22,984,115
- Address
- 225 Ne Mizner Blvd, Suite 640, BOCA RATON, 33432
- Web
- https://www.inmunebio.com/
- Phone
- +1 8589643720
- Auditors
- Marcum LLP
Upcoming Events for INMB
INmune Bio Inc Annual Shareholders Meeting
INmune Bio Inc Annual Shareholders Meeting
Q2 2025 INmune Bio Inc Earnings Release
Q3 2025 INmune Bio Inc Earnings Release
Similar to INMB
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Inmune Bio share price?
As of Today at 21:19 UTC, shares in Inmune Bio are trading at $7.76. This share price information is delayed by 15 minutes.
How has the Inmune Bio share price performed this year?
Shares in Inmune Bio last closed at $7.76 and the price had moved by -30.28% over the past 365 days. In terms of relative price strength the Inmune Bio share price has underperformed the S&P500 Index by -37.13% over the past year.
What are the analyst and broker recommendations for Inmune Bio?
The overall consensus recommendation for Inmune Bio is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Inmune Bio dividend yield?
Inmune Bio does not currently pay a dividend.
Does Inmune Bio pay a dividend?
Inmune Bio does not currently pay a dividend.
When does Inmune Bio next pay dividends?
Inmune Bio does not currently pay a dividend.
How do I buy Inmune Bio shares?
To buy shares in Inmune Bio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Inmune Bio?
As of the previous close price of $7.76, shares in Inmune Bio had a market capitalisation of $178.36m.
Where are Inmune Bio shares listed?
Here are the trading details for Inmune Bio:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: INMB
What kind of share is Inmune Bio?
Based on an overall assessment of its quality, value and momentum Inmune Bio is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Inmune Bio share price forecast for 2025?
The analyst consensus target price for shares in Inmune Bio is $23.40. That is 201.55% above the last closing price of $7.76.
Analysts covering Inmune Bio currently have a consensus Earnings Per Share (EPS) forecast of -$1.80 for the next financial year.
Find out moreWhat is the trend in the Inmune Bio share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Inmune Bio. Over the past six months, its share price has outperformed the S&P500 Index by +29.06%.
As of the last closing price of $7.76, shares in Inmune Bio were trading +15.33% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Inmune Bio PE Ratio?
The Inmune Bio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $7.76.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Inmune Bio?
We do not have data on Inmune Bio's directors